SIT161: A novel disease-modifying approach 
to treat & prevent neurodegenerative diseases (NDDs​)

European Biotech Company
About us

An exceptional molecule

SIT161 is an exceptional molecule that allows a highly innovative transnosological approach to fight NDDs with efficacy. 
As NDDs have a complex pathogenesis, they need a novel strategy to fight them efficiently. 

A perfect safety profile

SIT161 has already been tested in Ph. 2 clinical trials on 1.000+ subjects in another field of the CNS area. It showed a perfect safety profile allowing to target long-term treatments necessary in the approach of NDDs.  

High impact on NDDs

SIT161 targets simultaneously all major underlying mechanisms recognized by science in the pathogenesis of NDDs. 
Hence, it has exceptional disease-modifying impact and can be used for both treatment & prevention of NDDs. 

NDDs Disease Burden

Neurodegenerative disease is an umbrella term for a variety of conditions which primarily affect the neurons. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. 

Neurodegenerative diseases (NDDs) are currently incurable and severely impactful conditions due to progressive degeneration and death of nerve cells, resulting in  devastating and often fatal problems of mental function and movement. 

The economic burden of NDDs is tremendous and despite massive investment in research and drug development over the past decades, no promising treatment has been found so far to prevent or slow down disease progression in NDDs and in some indications, symptomatic treatments only are available today to bring some  relief  to a limited number of patients. 
  • The total yearly cost of dementia alone has reached a cost of US$ 1 trillion in 2018, which represents approximately more than 1% of global GDP.*
  • By 2020, the global worldwide cost for all neurodegenerative diseases is supposed to rise above US$ 2 trillion.*
  • There are more than 10 million new cases of NDDs each year worldwide, implying one new case every 3.2 seconds.*
  • Alzheimers and dementia alone are supposed to reach 131.5 million people in 2050 and the cost of dementia has increased by 35% since the 2010 according to the World Alzheimer Report.*
Given the epidemic scale of neurodegenerative diseases, with no known cure on the horizon, and with a global ageing population,  there is an urgent need for innovative, efficient and non-toxic approaches to treat and prevent those chronic diseases. 

It is uncommon to find a treatment that has both a high therapeutic potential and a high safety profile. 
SIT161 appears to fit both challenges and provides large advantages over most of the existing approaches driven actually in Phase 1-3 AD, PD, ALS, MS clinical trials. 

Interested in our developments?  

Contact-us

*References

  • Alzheimer and dementia: https://www.alz.co.uk/research/statistics
  • https://dhune.org/les-maladies-neurodegeneratives/?lang=en
  • https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf
  • Retinal degeneration: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2813%2970145-1/fulltext
Share by: